Redefining T2D and Obesity Management with GIP/GLP-1 receptor agonist

Time: 16:15 - 17:00
Hall: Congress Hall

Chair: Prof. Dr. med Martin Haluzik

Prof. Dr. med Martin Haluzik: The Need for proactive, comprehensive treatment of T2D and Obesity

Prof. Dr. med Tomasz Klupa: Targeting Adiposity as a Root Cause for T2D and Obesity

Dr. med Dr. Laxmi Narsimha Rao: New Horizons in Obesity Care

Prof. Dr. med Klupa: Incretin co-agonists in the Treatment of T2D

Panel Discussion

Treatment of cardiovascular continuum 2024: focus on novel opportunities

Time: 13:00 - 14:30
Hall: Congress Hall

Chair: R. Češka

L. Tokgözoğlu (Ankara, Turkey) How to get to LDL-C goal in the multimorbid patients?

A. Zambon (Padova, Italy) Beyond the usual suspects: TG-rich lipoproteins and Lp(a)

K. Narkiewicz (Gdansk, Poland) The silent killers: Advanced strategies for hypertension and obesity management

Invitation for symposium here

The many faces of B12-deficiency and necessity of multidisciplinary management

Time: 14:30 - 15:30
Hall: South Hall 1

R. Češka (Prague, Czech Republic) Optimizing Patient Care: Strategies for Managing Vitamin B12 Deficiency in Internal Medicine

R. Obeid (Hamburg, Germany) Practical Guidance for Diagnosing and Treating Vitamin B12 Deficiency: Results of an International and Multidisciplinary B12 Consensus Conference

B. Hooshmand (Tutzing, Germany) Vitamin B12 in Neurology: A Clinical Approach

Invitation for the symposium here

Comprehensive management of post ACS patients – how to improve and optimize secondary prevention?

Time: 15:30 - 16:30
Hall: Panorama Hall

Chair: R. Češka

A. Linhart (Prague, Czech Republic) - Dyslipidemia - an underappreciated risk factor in the context of a high-risk country

M. Vrablík (Prague, Czech Republic) - Fail no more. Lipid goals at our hands.

M. Kaluzna-Oleksy (Poznan, Poland) - Complex ACS management - the place of lipid lowering therapy and rehabilitation – learnings from MACAMIS program in Poland - ACS forum like an experience exchange platform

Time: 15:30 - 16:30
Hall: South Hall 1

C. Arias (Santo Domingo, Dominican Republic) Monkeypox

Q. T. Islam (Dhaka, Bangladesh) Emergencies in Dengue Syndrome

A. C. Cejudo (Mexico City, Mexico) Inflammatory process and the risk factors for cardiovascular diseases

E. Topinková (Prague, Czech Republic) Geriatrics

Time: 13:00 - 14:30
Hall: Congress Hall

Chair: R. Češka

R. Češka (Prague, Czech Republic) - Introduction

L. Tokgözoğlu (Ankara, Turkey) - CV risk reduction with lipid lowering: When and how?

M. Vrablík (Prague, Czech Republic) - The Power of Low LDL-C: Who Benefits Most and How Low is Enough

A. Zambon (Padova, Italy) - From research to clinical settings: PCSK9i Real Life Experience in Europe

Invitation for the symposium here

Session 1 - Elevated Lp(a)

Time: 14:30 - 15:30
Hall: Panorama Hall

Chairs: M. Vrablík, R. Češka

L. Tokgozoglu (Ankara, Turkey) ...The global problem 

A. Zambon (Padova, Italy) ... and CVD risk 

P. Lansberg (Amsterdam, Netherlands) ... and therapeutic approach 

Session 2 - Lp(a): policies, best practices and tips to enhance acceptance

Time: 15:30 - 16:30
Hall: Panorama Hall

M. Banach (Lodz, Poland)

R. Češka (Prague, Czech Republic)

K. Čillíkova (Czech Republic)

P. Lansberg (Amsterdam, Netherlands)

M. Rizzo (Palermo, Italy)

L. Tokgozoglu (Ankara, Turkey)

A. Zambon (Padova, Italy)

Topics to be discussed:

• To screen or not to screen for Lp(a) levels: roles of national and EU CVD plan
• When and how
• Examples of good practices
• How not to lose the information on elevated Lp(a)
• How to explain the topic to colleagues and patients 
• Which examinations and how frequently should be done in patients with elevated Lp(a) levels
• While we are awaiting the specific drugs targeting Lp(a) what shall we do to reduce the burden of elevated Lp(a) levels